title: Lack of correlation between NF-kappaB activation and induction of programmed cell death in PC12 pheochromocytoma cells treated with 6-hydroxydopamine or the cannabinoid receptor 1-agonist CP55,940.
abstract: NF-kappaB is a transcriptional regulator that plays a key role in immunity, inflammation and programmed cell death. We generated a PC12 cell line termed PC12kappaBluc that contains an integrated NF-kappaB-responsive reporter gene to directly measure NF-kappaB activity. The "classical" activators of NF-kappaB, phorbol 12-O-tetradecanoate-13-acetate and tumor necrosis factor alpha, strongly induced NF-kappaB activity in PC12kappaBluc cells. Activation of NF-kappaB could be attenuated by preincubating the cells with the cAMP analogue dbcAMP or via expression of the superrepressor IkappaBalphaS32A/S36A. PC12kappaBluc cells were subjected to several apoptotic paradigms, including treatment with 6-hydroxydopamine, H2O2, K2Cr2O7, MnCl2, C2-ceramide or the cannabinoid receptor-1 agonist CP55,940. A simultaneous measurement of the NF-kappaB activity revealed that only administration of 6-hydroxydopamine or CP55,940 increased NF-kappaB activity. Using pharmacological and genetic strategies to attenuate NF-kappaB transcriptional activity, we demonstrate that the elevation of NF-kappaB activity by 6-hydroxydopamine and CP55,940 is not an integral part of the apoptotic signaling cascade in PC12 cells.
authors.affiliation: Department of Medical Biochemistry and Molecular Biology, University of Saarland, Medical Center, Building 44, D-66421, Homburg, Germany.
authors.forename: Nina
authors.initials: N
authors.lastname: Erlandsson
authors.forename: Bernd
authors.initials: B
authors.lastname: Baumann
authors.forename: Oliver G
authors.initials: OG
authors.lastname: Rössler
authors.forename: Katrin
authors.initials: K
authors.lastname: Kaufmann
authors.forename: Klaus M
authors.initials: KM
authors.lastname: Giehl
authors.forename: Thomas
authors.initials: T
authors.lastname: Wirth
authors.forename: Gerald
authors.initials: G
authors.lastname: Thiel
mesh_terms: D018663:Adrenergic Agents / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis; D000242:Cyclic AMP / Q000378:metabolism; D003511:Cyclohexanols / Q000494:pharmacology*; D004268:DNA-Binding Proteins; D020672:I-kappa B Proteins; D007166:Immunosuppressive Agents / Q000494:pharmacology; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism*; D016627:Oxidopamine / Q000494:pharmacology*; D016716:PC12 Cells; D010673:Pheochromocytoma / Q000473:pathology; D051381:Rats; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D018663:Adrenergic Agents; D003511:Cyclohexanols; D004268:DNA-Binding Proteins; D020672:I-kappa B Proteins; D007166:Immunosuppressive Agents; D016328:NF-kappa B; C000606206:Nfkbia protein, rat; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D014409:Tumor Necrosis Factor-alpha; D000072000:NF-KappaB Inhibitor alpha; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; D016627:Oxidopamine; D000242:Cyclic AMP; D013755:Tetradecanoylphorbol Acetate